Table 5.
Pharmacokinetic Parameters of GKA After Oral Administration of GKA-SNEDDS and GKA-Suspension
| Parameters | GKA-Suspension | GKA-SNEDDS |
|---|---|---|
| Cmax (ng/mL) | 5.23 ± 2.14 | 24.33 ± 9.33** |
| Tmax(h) | 1.83 ± 1.12 | 1.17 ± 0.68 |
| AUC0-24 (ng·h/mL) | 26.31 ± 6.78 | 92.95 ± 22.89** |
| AUC0-∞ (ng·h/mL) | 30.98 ± 9.65 | 100.41 ± 20.31 |
| t1/2(h) | 7.66 ± 4.66 | 3.62 ± 1.37 |
| F (%) | — | 353.28 |
Notes: Data are expressed as mean ± SD (n = 6), **p < 0.001 as compared to GKA-suspension-treated group after oral administration, respectively.
Abbreviations: Tmax, the time of peak concentration; Cmax, the Peak of maximum concentration; AUC0-24, the area under the concentration–time profile curve of up to 24h; F, the relative bioavailability.